These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31263028)

  • 1. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.
    Willis JA; Overman MJ; Vilar E
    Clin Cancer Res; 2019 Sep; 25(17):5185-5187. PubMed ID: 31263028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
    Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
    Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.
    Willis JA; Overman MJ
    Cancer Discov; 2022 Jul; 12(7):1612-1614. PubMed ID: 35791694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
    Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
    J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
    Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
    Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
    Jones D; Guan JJ; Calagua C; Hansel DE; Epstein JI; Ye H
    Hum Pathol; 2019 Dec; 94():58-63. PubMed ID: 31666198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.
    Majumder B; Nataraj NB; Maitreyi L; Datta S
    Front Immunol; 2024; 15():1414376. PubMed ID: 39100682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas.
    Johncilla M; Chen Z; Sweeney J; Yantiss RK
    Am J Surg Pathol; 2018 Dec; 42(12):1686-1692. PubMed ID: 30179899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
    Pietrantonio F; Randon G; Romagnoli D; Di Donato S; Benelli M; de Braud F
    Cancer Treat Rev; 2020 Jan; 82():101935. PubMed ID: 31821983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency.
    Lazarev I; Leibovitch L; Czeiger D; Sion-Vardi N; Geffen DB; Douvdevani A; Ariad S
    In Vivo; 2014; 28(3):349-54. PubMed ID: 24815837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Negative Impact of Body Mass Index on the Tumor Microenvironment in Colon Cancer: Results of a Prospective Trial.
    Flaherty DC; Jalas JR; Sim MS; Stojadinovic A; Protic M; Lee DJ; Bilchik AJ
    Ann Surg Oncol; 2018 May; 25(5):1374-1380. PubMed ID: 29532344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.